PL3801536T3 - Podawanie sepiapteryny bez pożywienia do zastosowania w sposobie zwiększania ekspozycji osocza na sepiapterynę - Google Patents

Podawanie sepiapteryny bez pożywienia do zastosowania w sposobie zwiększania ekspozycji osocza na sepiapterynę

Info

Publication number
PL3801536T3
PL3801536T3 PL19811888.7T PL19811888T PL3801536T3 PL 3801536 T3 PL3801536 T3 PL 3801536T3 PL 19811888 T PL19811888 T PL 19811888T PL 3801536 T3 PL3801536 T3 PL 3801536T3
Authority
PL
Poland
Prior art keywords
sepiapterin
administration
food
increasing
plasma exposure
Prior art date
Application number
PL19811888.7T
Other languages
English (en)
Inventor
Neil Smith
Jonathan Reis
Original Assignee
Ptc Therapeutics Mp, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp, Inc. filed Critical Ptc Therapeutics Mp, Inc.
Publication of PL3801536T3 publication Critical patent/PL3801536T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL19811888.7T 2018-05-30 2019-05-30 Podawanie sepiapteryny bez pożywienia do zastosowania w sposobie zwiększania ekspozycji osocza na sepiapterynę PL3801536T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862677943P 2018-05-30 2018-05-30
US201862771398P 2018-11-26 2018-11-26
US201962822376P 2019-03-22 2019-03-22
GC201937663 2019-05-28
PCT/US2019/034523 WO2019232130A1 (en) 2018-05-30 2019-05-30 Methods for increasing sepiapterin plasma exposure

Publications (1)

Publication Number Publication Date
PL3801536T3 true PL3801536T3 (pl) 2025-02-03

Family

ID=68699037

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19811888.7T PL3801536T3 (pl) 2018-05-30 2019-05-30 Podawanie sepiapteryny bez pożywienia do zastosowania w sposobie zwiększania ekspozycji osocza na sepiapterynę

Country Status (20)

Country Link
US (2) US11617752B2 (pl)
EP (2) EP3801536B1 (pl)
JP (2) JP7502197B2 (pl)
CN (1) CN112703002A (pl)
AU (2) AU2019277382B2 (pl)
CA (1) CA3102106A1 (pl)
DK (1) DK3801536T3 (pl)
ES (1) ES2986920T3 (pl)
FI (1) FI3801536T3 (pl)
HR (1) HRP20241213T1 (pl)
HU (1) HUE068589T2 (pl)
LT (1) LT3801536T (pl)
MD (1) MD3801536T2 (pl)
MX (2) MX2020012979A (pl)
PL (1) PL3801536T3 (pl)
PT (1) PT3801536T (pl)
RS (1) RS65874B1 (pl)
SI (1) SI3801536T1 (pl)
SM (1) SMT202400430T1 (pl)
WO (1) WO2019232130A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102789662B1 (ko) 2016-11-29 2025-04-03 피티씨 테라퓨틱스 엠피, 인크. 세피아프테린의 다형체 및 그의 염
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
BR112020003865A8 (pt) 2017-09-01 2022-08-16 Censa Pharmaceuticals Inc Composições farmacêuticas compreendendo sepiapterina e seus usos
PL3801536T3 (pl) 2018-05-30 2025-02-03 Ptc Therapeutics Mp, Inc. Podawanie sepiapteryny bez pożywienia do zastosowania w sposobie zwiększania ekspozycji osocza na sepiapterynę
US12257252B2 (en) 2018-05-30 2025-03-25 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
EP4093405A1 (en) * 2020-01-24 2022-11-30 PTC Therapeutics MP, Inc. Methods for treating parkinson's disease with sepiapterin
US20230077104A1 (en) * 2020-02-19 2023-03-09 The United States Government As Represented By The Department Of Veteran Affairs L-sepiapterin and methods of use for treating diseases and disorders
WO2022173823A1 (en) * 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
IL305037A (en) * 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
CN120732846A (zh) * 2025-04-09 2025-10-03 中南大学湘雅医院 吲哚乙酸在制备预防或治疗高血压产品中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
EP0854934A4 (en) 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
EP1696877A4 (en) * 2003-11-13 2010-06-09 Gen Hospital Corp PROCESS FOR PAIN TREATMENT
CA2545484A1 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
EP3138566B1 (en) 2003-11-17 2022-01-26 BioMarin Pharmaceutical Inc. Treatment of phenylketonuria with bh4
EP1687308B1 (en) 2003-11-17 2019-06-12 Merck & Cie Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms
EP2436379A1 (en) 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
CA2588994A1 (en) 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
CN101163671B (zh) 2005-04-28 2011-05-11 白鸟制药株式会社 腙衍生物的制备方法
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
RU2486899C2 (ru) 2007-04-11 2013-07-10 Байомарин Фармасьютикал Инк. Композиции тетрагидробиоптерина и способы его количественной оценки
US20110144117A1 (en) 2008-08-12 2011-06-16 Orpha Swiss Gmbh Pharmaceutical Dosage Form Containing Tetrahydrobiopterin
US20130197000A1 (en) * 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
KR20140021585A (ko) 2011-03-01 2014-02-20 루비콘 리서치 피브이티. 엘티디. 테트라하이드로바이옵테린의 안정한 조성물
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
WO2013168693A1 (ja) 2012-05-07 2013-11-14 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
EP3213062B1 (en) 2014-10-31 2020-02-12 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
KR102789662B1 (ko) 2016-11-29 2025-04-03 피티씨 테라퓨틱스 엠피, 인크. 세피아프테린의 다형체 및 그의 염
BR112020003865A8 (pt) 2017-09-01 2022-08-16 Censa Pharmaceuticals Inc Composições farmacêuticas compreendendo sepiapterina e seus usos
CN115346478B (zh) * 2017-11-23 2025-09-02 株式会社半导体能源研究所 显示装置及电子设备
US12257252B2 (en) 2018-05-30 2025-03-25 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
KR20210038848A (ko) 2018-05-30 2021-04-08 피티씨 테라퓨틱스 엠피, 인크. 세피아프테린의 제약상 허용되는 염
PL3801536T3 (pl) 2018-05-30 2025-02-03 Ptc Therapeutics Mp, Inc. Podawanie sepiapteryny bez pożywienia do zastosowania w sposobie zwiększania ekspozycji osocza na sepiapterynę
SMT202500089T1 (it) 2019-08-05 2025-03-12 Univ Virginia Commonwealth Uso di sepiapterina e suoi metaboliti per trattare una esposizione alle radiazioni
EP4034122B1 (en) 2019-09-25 2025-08-13 PTC Therapeutics MP, Inc. Methods for treating hyperphenylalaninemia

Also Published As

Publication number Publication date
EP4454704A3 (en) 2025-01-01
EP3801536A4 (en) 2022-03-23
RS65874B1 (sr) 2024-09-30
MD3801536T2 (ro) 2024-11-30
US20230381181A1 (en) 2023-11-30
WO2019232130A1 (en) 2019-12-05
AU2019277382B2 (en) 2025-01-09
HRP20241213T1 (hr) 2024-11-22
MX2024005935A (es) 2024-06-04
LT3801536T (lt) 2024-09-25
US11617752B2 (en) 2023-04-04
HUE068589T2 (hu) 2025-01-28
EP4454704A2 (en) 2024-10-30
SI3801536T1 (sl) 2024-12-31
EP3801536A1 (en) 2021-04-14
JP7502197B2 (ja) 2024-06-18
US20210220363A1 (en) 2021-07-22
SMT202400430T1 (it) 2024-11-15
MX2020012979A (es) 2021-04-29
EP3801536B1 (en) 2024-07-17
ES2986920T3 (es) 2024-11-13
US12329757B2 (en) 2025-06-17
JP2021525729A (ja) 2021-09-27
FI3801536T3 (fi) 2024-08-29
JP2024069192A (ja) 2024-05-21
AU2025200814A1 (en) 2025-02-27
CA3102106A1 (en) 2019-12-05
CN112703002A (zh) 2021-04-23
DK3801536T3 (da) 2024-08-19
AU2019277382A1 (en) 2021-01-21
PT3801536T (pt) 2024-09-19

Similar Documents

Publication Publication Date Title
HUE068589T2 (hu) Szepiapterin beadása táplálék nélkül szepiapterin-plazmaexpozíciót növelõ eljárásban való alkalmazásra
IL279632A (en) Compounds and Methods for Reducing LRRK2 Expression
IL263093B (en) Plasma-based coatings and methods for their preparation and use
IL279101A (en) Salts of spiafatrin are accepted in pharmacies
PL3043749T3 (pl) System i sposób podawania implantu do anuloplastyki
EP3272254A4 (en) Plasma non-stick pan and method for manufacturing same
SMT202500241T1 (it) Elafibranor per uso nel trattamento di colangite biliare primitiva
EP3522795A4 (en) METHOD AND DEVICE FOR STENT INSERTION
PT3286166T (pt) Inibidores de replicação do vírus da imunodeficiência humana
EP2904905B8 (en) An apparatus for aligning and positioning pieces of food dough
GB201516802D0 (en) Apparatus and method for determination of the dose of a powder inhalation formulation
SMT202100468T1 (it) 24-idrossisteroli sostituiti in posizione 11 per l'uso nel trattamento delle condizioni correlate all'nmda
EP3096763A4 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
IL248288A0 (en) Device and method for preparing and administering blood components
GB2541049B (en) Method for forming multilayer coated film
PL3111929T3 (pl) Ulegający rozpadowi w jamie ustnej preparat w postaci błony zawierający tadalafil i sposób jego wytwarzania
GB2532606B (en) Multiple camera apparatus and method for synchronized autofocus
EP3876307C0 (en) FILM PRODUCTION PROCESS
SG11201709707TA (en) Method for reducing the defectivity of a block copolymer film
ZA202204143B (en) Film and preparation method thereof
EP3198745A4 (en) Method and network node for facilitating timing synchronization in network
IL275486A (en) Formulation of a layer containing vardenafil, method for its preparation and use
HUP1400104A2 (en) Compositions comprising indometacine, its pharmaceutically acceptable salts and cocrystals; and process for the preparation
GB201417597D0 (en) Film dispenser and method for manufacture thereof
PL422715A1 (pl) Fotel do wstępnego pozycjonowania pacjenta